Advanced Solid Tumors MedDRA version: 21.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 21.1 Level: PT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma Syst
Conditions
Interventions
Product Code: ALKS 4230
Pharmaceutical Form: Lyophilisate for suspension for injection
INN or Proposed INN: ALKS 4230
Current Sponsor code: ALKS 4230
Other descriptive name: ALKS 4230
Concentration un
Sponsors
Alkermes, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subject is aged =18 years. 2. Subject or the subject’s legal representative provides written informed consent. 3. For Phase 1, subject must have an advanced solid tumor (including lymphoma) and progressive disease following at least one line of therapy. 4. For Phase 2, subject must have one of the following tumor types or specific histology: • NSCLC cohort: subjects with Stage IIIB or IV NSCLC who have been treated with a checkpoint inhibitor(s) with a response stable disease or better and followed by progression more than 120 days after initiation of the checkpoint inhibitor therapy. • SCCHN cohort: subjects with regionally advanced and/or distantly metastatic head and neck squamous cell carcinoma of non-cutaneous origin that has relapsed or failed to achieve complete response after at least one line of systemic therapy given alone or in combination with surgery and /or radiation therapy • Non-squamous head and neck cancer cohort: subjects with regionally advanced and/or distantly metastatic head and neck cancer of non-squamous cell origin. •Squamous tumor agnostic of anatomic etiology cohort: subjects with recurrent or metastatic squamous cell carcinoma (SCC), regardless of tissue origin, following chemotherapy and who have not received prior checkpoint inhibitor therapy. • HCC cohort: subjects with recurrent or metastatic HCC with disease progression on or after systemic antitumor therapy who have not received prior checkpoint inhibitor therapy. • SCLC cohort: subjects with unresectable or metastatic SCLC who have progressed on or after a minimum of 4 cycles of chemotherapy. •Ovarian cancer cohort: subjects must have recurrent high-grade serous, endometrioid,or clear cell ovarian, fallopian tube, or primary peritoneal cancer. 5. Subject must have at least one target lesion based on RECIST. 6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 and an estimated life expectancy of at least 3 months.. 7. Subject has adequate hematologic reserves, measured within 7 days prior to start of study treatment, as defined in the protocol 8. Subject has adequate hepatic function as evidenced by aspartate transaminase and alanine aminotransferase values =3 × the upper limit of normal (ULN) (=5 × ULN if the liver is known to be involved by metastatic disease) and serum total bilirubin values of =1.5 × ULN (=2 × ULN for subjects with known Gilbert’s syndrome) for the reference laboratory measured within 10 days prior to start of study treatment. 9. Subject has adequate renal function as evidenced by a serum creatinine =1.5 × ULN for the reference laboratory or a calculated creatinine clearance of =45 mL/min by the Cockroft-Gault equation measured within 10 days prior to start of study treatment. 10. Subject has recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy, or surgery (ie, toxicity no worse than Grade 1 [any grade alopecia and treatment-associated peripheral neuropathy are acceptable]). 11. Subject who has received standard or investigational antineoplastic agents must wait at least 5 half-lives or 4 weeks, whichever is shorter, before enrollment into the study or 4 weeks if the half-life of the investigational agent is not known. Subjects may be enrolled within 3 weeks of previous treatment upon agreement between Medical Monitor and Principal Investigator. 12. Women of childbearing potential (WOCBP) must hav
Exclusion criteria
Exclusion criteria: 1. Subject is currently pregnant or breastfeeding or is planning to become pregnant during the study period. 2. Subjects who are investigational site staff members directly involved in the conduct of the trial and their immediate family members, or subjects who are Alkermes or Syneos Health employees directly involved in the conduct of the study. 3. Subject has an active infection or a fever =38.5°C (=101°F) within 3 days of the first scheduled day of dosing for the monotherapy lead-in of Phase 1 or Cycle 1 of Phase 2. 4. Subjects who have received therapeutic systemic antibiotics within 14 days prior to starting investigational therapy excluded unless specifically exempted on a case-by-case basis by the Medical Monitor. 5.Subject has known hypersensitivity (Grade =3) to any components of ALKS 4230, to pembrolizumab, or any of its excipients. 6. .Subjects with mean QT interval corrected by the Fridericia Correction Formula values of >470 msec (in females) or >450 msec (in males) following a standard 12-lead electrocardiogram (ECG); subjects who are known to have congenital prolonged QT syndromes; or subjects who are on medications known to cause prolonged QT interval on ECG. 7. Subject has developed Grade =3 autoimmune disorders while on prior immunotherapy,(eg, pneumonitis, nephritis, and neuropathy). Subjects who have immune-mediated endocrinopathies and are stable on hormone replacement therapy are not excluded. Subjects who developed other autoimmune disorders of Grade =2 may enroll if the disorder has resolved and the subject is off systemic steroids for =28 days. Subjects who experienced autoimmune colitis as a toxicity of prior immunotherapy must undergo colonoscopy to rule out ongoing inflammation. Vitiligo is not exclusionary. Subjects who developed other autoimmune disorders of Grade =3 may enroll if the disorder has resolved and the subject is off steroids for 2 weeks. Subjects who experienced autoimmune colitis as a toxicity of prior immunotherapy must undergo or must have been evaluated by colonoscopy to rule out ongoing inflammation. 8.Subjects who have received radiotherapy within the last 4 weeks before start of study treatment, with the exception of limited field palliative radiotherapy that has been completed at least 2 weeks before starting study treatment. 9. Subject has an active or symptomatic central nervous system metastases unless the metastases have been treated by surgery and /or radiation therapy, the subject has been dose, and the subject is neurologically stable. 10. Subject has an active autoimmune disease that has required systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease that has required systemic steroids and/or immunosuppressive agents. Limited exceptions may be granted on a case-by-case basis by the Medical Monitor. 11. Subjects known to be positive for human immunodeficiency virus are excluded. Exceptions please see in the protocol. 12. Subjects with active tuberculosis or a known history of tuberculosis are excluded. 13. Subjects requiring pharmacologic doses of systemic corticosteroids (greater than 10 mg of prednisone daily, or equivalent) are excluded. 14. Subject has had a second malignancy within the previous 3 years. This criterion does not apply to subjects with an adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, prostate cancer of highest Gleason score =6 with undet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: - To characterize the safety and tolerability and to identify the recommended Phase 2 dose (RP2D) of ALKS 4230 administered subcutaneously (SC) as lead-in monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors (Phase 1) - To characterize the safety profile of SC ALKS 4230 at the RP2D in combination with pembrolizumab in subjects with advanced solid tumors (Phase 2) - To estimate the clinical activity of combination treatment with ALKS 4230 and pembrolizumab in terms of overall response rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 separately for -Non–small-cell lung cancer (NSCLC) -Squamous cell carcinoma of the head and neck (SCCHN) - Non-squamous head and neck cancers -Squamous tumors agnostic of anatomic etiology -Hepatocellular carcinoma (HCC) -Small-cell lung cancer (SCLC) -Ovarian cancer (Phase 2);Secondary Objective: - To describe dose-limiting toxicity (DLT) for SC ALKS 4230 lead-in monotherapy (Phase 1) - To characterize the pharmacokinetics (PK), clinical pharmacodynamics (PD), and immunogenicity of SC ALKS 4230 as lead-in monotherapy (Phase 1) and in combination with pembrolizumab (Phase 1 and Phase 2) - To describe antitumor activity observed with SC ALKS 4230 as lead-in monotherapy and in combination with pembrolizumab (Phase 1) - To evaluate antitumor efficacy in subjects treated with SC ALKS 4230 in combination with pembrolizumab (Phase 2);Primary end point(s): - The incidence and severity of treatment-emergent adverse events (AEs) (Phase 1 and Phase 2) - ORR based on RECIST 1.1 (Phase 2);Timepoint(s) of evaluation of this end point: Treatment-emergent AEs will be evaluated during every visit at the clinic. Antitumor activity will be determined by the measurement of extent of known disease at baseline and approximately every 9 weeks. After Cycle 10, this should be reduced to every 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - The incidence of DLTs from the beginning of first dose of investigational agent (s) through the end of the DLT observation period (Phase 1) - Serum concentrations of ALKS 4230 and descriptive PK parameters (Phase 1 and Phase 2) - Presence of anti-ALKS 4230 antibodies in serum (Phase 1 and Phase 2) - Numbers of circulating cluster of differentiation (CD)8 T cells, T regulatory cells (Tregs), and natural killer cells in peripheral blood (Phase 1 and Phase 2) - Serum levels of interleukin-6 and other cytokines (Phase 1 and Phase 2) - ORR, Disease Control Rate (DCR), Duration of Response (DOR), Time to Response (TTR),and Progression-free Survival (PFS) per RECIST 1.1 (Phase 1) - Immune ORR (iORR), immune DCR (iDCR), immune DOR (iDOR), immune TTR (iTTR), and immune PFS (iPFS) per immune RECIST (iRECIST) (Phase 1) - DCR, DOR, TTR, and PFS, per RECIST 1.1 (Phase 2) - iORR, iDCR, iDOR, iTTR, and iPFS, per iRECIST (Phase 2) - Overall survival (OS) (Phase 2);Timepoint(s) of evaluation of this end point: Serum samples for evaluation of ALKS 4230 PK and patient immunogenicity will be obtained from each subject at predetermined time points. Antitumor activity will be determined by the measurement of extent of known disease at baseline and approximately every 9 weeks. After Cycle 10, this should be reduced to every 12 weeks. | — |
Countries
France, Germany, Korea, Republic of, Netherlands, Spain, Taiwan, United Kingdom, United States
Contacts
Public ContactJennifer Skinner
Syneos Health
Outcome results
None listed